StockData
Neuphoria Therapeutics Inc. logo

Neuphoria Therapeutics Inc. (NEUP) stock

NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026Score 5/30
$2.48−0.07 (-2.75%)

Close on Nov 16, 2026Market cap $74.56KP/E –Yield –

Neuphoria Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Neuphoria Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$16.45M. For fiscal 2026 it was -$16.45M.

Annual operating income

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$16.45M–
FY2025Jun 30, 2025-$1.13M–
FY2024Jun 30, 2024-$17.89M–
FY2023Jun 30, 2023-$21.98M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026-$5.53M–
Q3 FY2026CQ1 2026Mar 31, 2026-$1.21M-110.1%
Q2 FY2026CQ4 2025Dec 31, 2025-$4.06M–
Q1 FY2026CQ3 2025Sep 30, 2025-$5.65M–
Q4 FY2025CQ2 2025Jun 30, 2025-$5.84M–
Q3 FY2025CQ1 2025Mar 31, 2025$11.98M–
Q2 FY2025CQ4 2024Dec 31, 2024-$3.70M–
Q1 FY2025CQ3 2024Sep 30, 2024-$3.57M–
Q4 FY2024CQ2 2024Jun 30, 2024-$5.48M–
Q3 FY2024CQ1 2024Mar 31, 2024-$2.39M–
Q2 FY2024CQ4 2023Dec 31, 2023-$4.55M–
Q1 FY2024CQ3 2023Sep 30, 2023-$5.47M–

More Neuphoria Therapeutics figures

See a number that looks wrong?